Skip to main content

Table 2 Relative expression of tenascin-C, AD1 and AD2 in cell lines and isolated normal breast cells

From: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women

 

Number of TNC transcripts (×103)

% of total TNC transcripts

Cell line

Total TNC

AD1

AD2

AD1

AD2

ZR-75-1

0

0

0

0

0

T-47D

0

0

0

0

0

MCF-7

0

0

0

0

0

Hs578T

162.651

41.432

14.574

25.47

8.96

MDA-MB-231

1,293.947

44.383

23.821

3.43

1.84

MDA-MB-436

8,409.526

479.824

55.735

5.71

0.66

MDA-MB-468

984.727

89.74

28.784

9.11

2.92

GI-101

1,529.834

143.854

8.433

9.40

0.55

HBL-100

15,017.045

6,671.261

483.212

44.42

3.22

MCF-10A

91.37

7.399

6.933

8.10

7.59

Primary MEC

2,925.394

1,863.143

142.39

63.69

4.87

Primary fibroblasts

5398.821

87.867

98.044

1.63

1.82

  1. Percentage expression of additional domain (AD) 1 and AD2 relative to the invariant exon 17/18 boundary, as a marker of total tenascin-C (TNC) expression, normalised to the hypoxanthine phosphoribosyltransferase 1 control in cell lines and isolated normal breast cells. MEC, myoepithelial cells.